Bayer HealthCare Pharmaceuticals has announced enrollment of the first patient in an international phase III open-label, multicenter, nonrandomized, single-dose clinical trial to evaluate the efficacy and safety of its new PET imaging agent.
Florbetaben (BAY 94-9172) is used to detect beta-amyloid plaques in the brain, which are the pathological hallmark of Alzheimer's disease, according to the Wayne, NJ-based company.
At present, diagnosis of Alzheimer's disease is based on cognitive tests that only indicate a probability of having the disease, with definitive diagnosis confirmed by postmortem autopsy or brain tissue biopsy.
Related Reading
Bayer partners with Hamamatsu, January 12, 2009
Bayer Schering, Epix to end Vasovist partnership, September 4, 2008
Bayer awarded Amerinet deal, April 14, 2008
Bayer announces ship date for VistaTrak, March 13, 2008
Bayer inks molecular imaging deal, February 20, 2008
Copyright © 2009 AuntMinnie.com